Enhertu

NICE approves Enhertu for about 1,000 English women with HER2‑low breast cancer

Around 1,000 women each year with HER2‑low advanced breast cancer in England will be offered the drug Enhertu from Thursday, following NICE’s routine‑use recommendation and a new £35,000 per‑patient spending limit.